

# Eileen M O'reilly

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6260603/publications.pdf>

Version: 2024-02-01

293  
papers

19,820  
citations

14655

66  
h-index

13379

130  
g-index

300  
all docs

300  
docs citations

300  
times ranked

21542  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pancreatic cancer: Cutaneous metastases, clinical descriptors and outcomes. <i>Cancer Medicine</i> , 2023, 12, 179-188.	2.8	5
2	Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405. <i>Journal of the National Cancer Institute</i> , 2022, 114, 427-435.	6.3	24
3	Induction FOLFIRINOX for patients with locally unresectable pancreatic ductal adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2022, 125, 425-436.	1.7	6
4	Age and comorbidity association with survival outcomes in metastatic colorectal cancer: CALGB 80405 analysis. <i>Journal of Geriatric Oncology</i> , 2022, 13, 469-479.	1.0	3
5	Feasibility and utility of synthetic control arms derived from real-world data to support clinical development.. <i>Journal of Clinical Oncology</i> , 2022, 40, 528-528.	1.6	3
6	Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by <i>NRG1</i> Gene Rearrangements. <i>Cancer Discovery</i> , 2022, 12, 1233-1247.	9.4	60
7	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. <i>Cell</i> , 2022, 185, 563-575.e11.	28.9	223
8	Neoadjuvant FOLFIRINOX in borderline resectable and locally advanced pancreatic adenocarcinoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, , .	1.1	1
9	Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance). <i>Endocrine-Related Cancer</i> , 2022, 29, 335-344.	3.1	8
10	Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance). <i>Clinical Cancer Research</i> , 2022, 28, 2779-2788.	7.0	11
11	Venous Thromboprophylaxis in Surgical Oncology Patients: The Importance of Risk Assessment in the Context of Limited Evidence. <i>Journal of Clinical Oncology</i> , 2022, , JCO2102935.	1.6	1
12	Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. <i>Nature Medicine</i> , 2022, 28, 1167-1177.	30.7	112
13	Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer. <i>Cancer</i> , 2022, 128, 2958-2966.	4.1	2
14	Homologous Recombination Deficiency in Pancreatic Cancer: Poly (ADP-ribose) Polymerase Inhibition, Checkpoint Inhibition, or a Combination of Both?. <i>JCO Precision Oncology</i> , 2022, , .	3.0	1
15	Concurrent Germline <i>BRCA1</i> and <i>BRCA2</i> and Mismatch Repair Mutations in Young-Onset Pancreatic and Colorectal Cancer: The Importance of Comprehensive Germline and Somatic Characterization to Inform Therapeutic Options. <i>JCO Precision Oncology</i> , 2022, , .	3.0	2
16	Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2-positive metastatic pancreatic cancer (mPC): Phase 2, open-label, randomized study.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS4186-TPS4186.	1.6	2
17	Precision Medicine and Immunotherapy in GI Cancers. <i>Journal of Clinical Oncology</i> , 2022, 40, 2659-2661.	1.6	2
18	Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 3929-3939.	1.6	66

#	ARTICLE	IF	CITATIONS
19	Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 783-791.e1.	4.9	16
20	Preoperative CT predictors of survival in patients with pancreatic ductal adenocarcinoma undergoing curative intent surgery. <i>Abdominal Radiology</i> , 2021, 46, 1607-1617.	2.1	4
21	IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa074.	2.9	6
22	Prognostic value of the Memorial Sloan Kettering Prognostic Score in metastatic pancreatic adenocarcinoma. <i>Cancer</i> , 2021, 127, 1568-1575.	4.1	9
23	CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. <i>Lancet Oncology</i> , The, 2021, 22, 118-131.	10.7	177
24	Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 378-378.	1.6	59
25	Pancreatic ductal adenocarcinoma in the era of precision medicine. <i>Seminars in Oncology</i> , 2021, 48, 19-33.	2.2	8
26	Early-Onset Pancreas Cancer: Clinical Descriptors, Genomics, and Outcomes. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1194-1202.	6.3	35
27	Leptomeningeal disease in pancreas ductal adenocarcinoma: A manifestation of longevity. <i>Pancreatology</i> , 2021, 21, 599-605.	1.1	4
28	Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1277.	7.4	63
29	Pancreatic cancer stem cells may define tumor stroma characteristics and recurrence patterns in pancreatic ductal adenocarcinoma. <i>BMC Cancer</i> , 2021, 21, 385.	2.6	24
30	Pancreas cancer: Therapeutic trials in metastatic disease. <i>Journal of Surgical Oncology</i> , 2021, 123, 1475-1488.	1.7	11
31	Association of Ablative Radiation Therapy With Survival Among Patients With Inoperable Pancreatic Cancer. <i>JAMA Oncology</i> , 2021, 7, 735.	7.1	101
32	Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS. <i>Nature Communications</i> , 2021, 12, 3770.	12.8	68
33	Clinical Trials of Systemic Chemotherapy for Resectable Pancreatic Cancer. <i>JAMA Surgery</i> , 2021, 156, 663.	4.3	30
34	Local Control and Survival After Induction Chemotherapy and Ablative Radiation Versus Resection for Pancreatic Ductal Adenocarcinoma With Vascular Involvement. <i>Annals of Surgery</i> , 2021, 274, 894-901.	4.2	15
35	Treatment patterns and survival in patients with early-onset pancreatic cancer. <i>Cancer</i> , 2021, 127, 3566-3578.	4.1	20
36	Therapeutic Implications of Germline Testing in Patients With Advanced Cancers. <i>Journal of Clinical Oncology</i> , 2021, 39, 2698-2709.	1.6	83

#	ARTICLE	IF	CITATIONS
37	Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single-arm, phase 2 study. <i>Cancer</i> , 2021, 127, 4585-4593.	4.1	7
38	Retrospective Case Series Analysis of <i>RAF</i> Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies. <i>JCO Precision Oncology</i> , 2021, 5, 1325-1338.	3.0	14
39	Targeting DNA damage repair pathways in pancreas cancer. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 891-908.	5.9	18
40	Pancreas cancer and <i>BRCA</i> : A critical subset of patients with improving therapeutic outcomes. <i>Cancer</i> , 2021, 127, 4393-4402.	4.1	24
41	Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 2803-2815.	1.6	58
42	Pancreatic Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 851.	7.4	658
43	Prognostic value of tumor deposits in stage III colon cancer patients, a post-hoc analysis of CALGB/SWOG 80702 phase III study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 10-10.	1.6	0
44	Multimodality therapy in metastatic pancreas cancer with a <i>BRCA</i> mutation and durable long-term outcome: biology, intervention, or both?. <i>Cancer Biology and Therapy</i> , 2021, 22, 532-536.	3.4	1
45	Pharmacologically controlling protein-protein interactions through epichaperomes for therapeutic vulnerability in cancer. <i>Communications Biology</i> , 2021, 4, 1333.	4.4	11
46	Immune Landscape of Pancreas Ductal Adenocarcinoma: Current Therapeutic Strategies and Future Perspective. , 2021, , 221-255.		0
47	A Review of Pancreatic Cancer-Reply. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 2436.	7.4	4
48	A mixed methods analysis of patients' advance care planning values in outpatient oncology: Person-Centered Oncologic Care and Choices (P-COCC). <i>Supportive Care in Cancer</i> , 2020, 28, 1109-1119.	2.2	5
49	Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance). <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz078.	2.9	22
50	PD-1 Blockade in Advanced Adrenocortical Carcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 71-80.	1.6	119
51	Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma. <i>Investigational New Drugs</i> , 2020, 38, 800-811.	2.6	106
52	Liver and Bile Duct Cancer. , 2020, , 1314-1341.e11.		8
53	A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma. <i>Nature Cancer</i> , 2020, 1, 59-74.	13.2	124
54	Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa024.	2.9	8

#	ARTICLE	IF	CITATIONS
55	Reducing nihilism in metastatic pancreatic ductal adenocarcinoma: Treatment, sequencing, and effects on survival outcomes. <i>Cancer Medicine</i> , 2020, 9, 8480-8490.	2.8	5
56	Reply to G.W. Peters et al and S. Shi et al. <i>Journal of Clinical Oncology</i> , 2020, 38, 2947-2948.	1.6	0
57	Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a pre-specified subgroup analysis of the randomized CASSINI study. <i>Cancer Medicine</i> , 2020, 9, 6196-6204.	2.8	20
58	Molecular profiling and analysis of genetic aberrations aimed at identifying potential therapeutic targets in fibrolamellar carcinoma of the liver. <i>Cancer</i> , 2020, 126, 4126-4135.	4.1	5
59	Metastatic Pancreatic Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2020, 38, 3217-3230.	1.6	151
60	Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers. <i>Cell</i> , 2020, 182, 1044-1061.e18.	28.9	691
61	BRCA gene mutations as an emerging biomarker for the treatment of gastrointestinal malignancies. <i>Chinese Clinical Oncology</i> , 2020, 9, 64-64.	1.2	3
62	Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2020, 6, 1713.	7.1	24
63	Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib. <i>Cancer Medicine</i> , 2020, 9, 7453-7459.	2.8	11
64	Association of Diet Quality With Survival Among People With Metastatic Colorectal Cancer in the Cancer and Leukemia B and Southwest Oncology Group 80405 Trial. <i>JAMA Network Open</i> , 2020, 3, e2023500.	5.9	8
65	Duration of therapy for locally advanced pancreatic cancer: Does it matter?. <i>Cancer Medicine</i> , 2020, 9, 4572-4580.	2.8	10
66	Reply to N. Fazio. <i>Journal of Clinical Oncology</i> , 2020, 38, 2467-2468.	1.6	1
67	A Multicenter Randomized Three-Arm Phase II Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) with Leuprolide + Letrozole, and (3) Everolimus + EDT in Patients with Unresectable Fibrolamellar Carcinoma. <i>Oncologist</i> , 2020, 25, 925-e1603.	3.7	17
68	Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma. <i>Cancer</i> , 2020, 126, 3939-3949.	4.1	44
69	The Evolutionary Origins of Recurrent Pancreatic Cancer. <i>Cancer Discovery</i> , 2020, 10, 792-805.	9.4	71
70	Neoadjuvant or Adjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer: Which Is Preferred?. <i>Journal of Clinical Oncology</i> , 2020, 38, 1757-1759.	1.6	19
71	Germline alterations in patients with biliary tract cancers: A spectrum of significant and previously underappreciated findings. <i>Cancer</i> , 2020, 126, 1995-2002.	4.1	26
72	Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 41.	2.8	68

#	ARTICLE	IF	CITATIONS
73	Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline <i>BRCA/PALB2</i> Mutation. <i>Journal of Clinical Oncology</i> , 2020, 38, 1378-1388.	1.6	265
74	Reply to Nutritional support in pancreatic cancer. <i>Cancer</i> , 2020, 126, 1811-1812.	4.1	0
75	Genetic and clinical correlates of entosis in pancreatic ductal adenocarcinoma. <i>Modern Pathology</i> , 2020, 33, 1822-1831.	5.5	40
76	New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma. <i>Drugs</i> , 2020, 80, 647-669.	10.9	97
77	An Emerging Paradigm for Germline Testing in Pancreatic Ductal Adenocarcinoma and Immediate Implications for Clinical Practice. <i>JAMA Oncology</i> , 2020, 6, 764.	7.1	35
78	Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinoma. <i>European Journal of Cancer</i> , 2020, 132, 112-121.	2.8	22
79	Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection. <i>Clinical Cancer Research</i> , 2020, 26, 3239-3247.	7.0	135
80	NAPOLI-3: An open-label, randomized, phase III study of first-line liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin versus nab-paclitaxel + gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS4661-TPS4661.	1.6	9
81	A phase II study of siG12D-LODER in combination with chemotherapy in patients with locally advanced pancreatic cancer (PROTACT).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS4672-TPS4672.	1.6	29
82	Pancreatic cancer (PaC)-specific health-related quality of life (HRQoL) with maintenance olaparib (O) in patients (pts) with metastatic (m) PaC and a germline BRCA mutation (gBRCAm): Phase III POLO trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 648-648.	1.6	3
83	Young-onset pancreas cancer (PC) in patients less than or equal to 50 years old at Memorial Sloan Kettering (MSK): Descriptors, genomics, and outcomes.. <i>Journal of Clinical Oncology</i> , 2020, 38, 774-774.	1.6	5
84	Landscape of DNA-damage-repair/homologous recombination deficiency (DDR/HRD) in hepatopancreaticobiliary (HPB) cancers.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4620-4620.	1.6	0
85	Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405. <i>Journal of Clinical Oncology</i> , 2019, 37, 2620-2631.	1.6	51
86	Perioperative Gemcitabine+ Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. <i>Annals of Surgical Oncology</i> , 2019, 26, 4489-4497.	1.5	19
87	Pancreatic cancer—A disease in need: Optimizing and integrating supportive care. <i>Cancer</i> , 2019, 125, 3927-3935.	4.1	69
88	Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma. <i>JAMA Oncology</i> , 2019, 5, 1431.	7.1	417
89	Tumour lineage shapes BRCA-mediated phenotypes. <i>Nature</i> , 2019, 571, 576-579.	27.8	295
90	A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer. <i>Cancer Medicine</i> , 2019, 8, 5148-5157.	2.8	60

#	ARTICLE	IF	CITATIONS
91	Evolution of surgical management of gallbladder carcinoma and impact on outcome: results from two decades at a single-institution. <i>Hpb</i> , 2019, 21, 1541-1551.	0.3	16
92	Second-line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes. <i>Cancer</i> , 2019, 125, 4426-4434.	4.1	49
93	Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma. <i>JAMA Oncology</i> , 2019, 5, 1582.	7.1	91
94	Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib. <i>Annals of Oncology</i> , 2019, 30, 1959-1968.	1.2	37
95	Retooling a Blood-Based Biomarker: Phase I Assessment of the High-Affinity CA19-9 Antibody HuMab-5B1 for Immuno-PET Imaging of Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 7014-7023.	7.0	47
96	Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 317-327.	27.0	1,521
97	Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review. <i>Cancer Treatment Reviews</i> , 2019, 75, 27-38.	7.7	32
98	Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 286-295.	1.6	397
99	Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 720-728.	27.0	520
100	Binimetinib plus Gemcitabine and Cisplatin Phase I/II Trial in Patients with Advanced Biliary Cancers. <i>Clinical Cancer Research</i> , 2019, 25, 937-945.	7.0	22
101	Regional differences in gallbladder cancer pathogenesis: Insights from a multi-institutional comparison of tumor mutations. <i>Cancer</i> , 2019, 125, 575-585.	4.1	34
102	Genomic Landscape of Pancreatic Adenocarcinoma in Younger versus Older Patients: Does Age Matter?. <i>Clinical Cancer Research</i> , 2019, 25, 2185-2193.	7.0	41
103	Ampullary cancer: Evaluation of somatic and germline genetic alterations and association with clinical outcomes. <i>Cancer</i> , 2019, 125, 1441-1448.	4.1	28
104	A synonymous germline variant PALB2 c.18G>T (p.Gly6=) disrupts normal splicing in a family with pancreatic and breast cancers. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 79-86.	2.5	4
105	Abstract PR02: Clinical proof of concept for MCLA-128, a bispecific HER2/3 antibody therapy, in NRG1 fusion-positive cancers. , 2019, , .		26
106	Abstract CT004: A Phase Ib study of CD40 agonistic monoclonal antibody APX005M together with gemcitabine (Gem) and nab-paclitaxel (NP) with or without nivolumab (Nivo) in untreated metastatic ductal pancreatic adenocarcinoma (PDAC) patients. , 2019, , .		44
107	Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a prespecified subgroup analysis of the CASSINI study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4016-4016.	1.6	8
108	Guidelines Insights: Pancreatic Adenocarcinoma, Version 1.2019. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 202-210.	4.9	281



#	ARTICLE	IF	CITATIONS
109	Incidence, Management, and Implications of Visceral Thrombosis in Pancreatic Ductal Adenocarcinoma. <i>Clinical Colorectal Cancer</i> , 2018, 17, 121-128.	2.3	21
110	Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1067-1074.	6.3	170
111	Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. <i>Lancet Oncology</i> , The, 2018, 19, e151-e160.	10.7	51
112	Brain Metastases in Pancreatic Ductal Adenocarcinoma: Assessment of Molecular Genotypeâ€œPhenotype Featuresâ€œAn Entity With an Increasing Incidence?. <i>Clinical Colorectal Cancer</i> , 2018, 17, e315-e321.	2.3	13
113	Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline <i>BRCA</i> mutation carriers and wildâ€œtype <i>BRCA</i> pancreatic ductal adenocarcinoma. <i>Cancer</i> , 2018, 124, 1374-1382.	4.1	91
114	Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations. <i>Clinical Cancer Research</i> , 2018, 24, 1326-1336.	7.0	281
115	Biomarker-Based Therapy in Pancreatic Ductal Adenocarcinoma: An Emerging Reality?. <i>Clinical Cancer Research</i> , 2018, 24, 2241-2250.	7.0	32
116	Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 50-58.	4.9	41
117	Visceral Thromboses in Pancreas Adenocarcinoma: Systematic Review. <i>Clinical Colorectal Cancer</i> , 2018, 17, e207-e216.	2.3	9
118	A Randomized Trial of Acceptability and Effects of Values-Based Advance Care Planning in Outpatient Oncology: Person-Centered Oncologic Care and Choices. <i>Journal of Pain and Symptom Management</i> , 2018, 56, 169-177.e1.	1.2	24
119	Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies. <i>Investigational New Drugs</i> , 2018, 36, 683-695.	2.6	75
120	Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma. <i>European Journal of Cancer</i> , 2018, 89, 19-26.	2.8	125
121	Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2018, 36, 2545-2556.	1.6	204
122	Understanding Pancreatic Diseases Using Animated Pancreas Patient. <i>Pancreas</i> , 2018, 47, 1256-1261.	1.1	8
123	Acquired resistance to immunotherapy in MMR-D pancreatic cancer. , 2018, 6, 127.		27
124	Circulating Tumor and Invasive Cell Gene Expression Profile Predicts Treatment Response and Survival in Pancreatic Adenocarcinoma. <i>Cancers</i> , 2018, 10, 467.	3.7	12
125	Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention. <i>Clinical Cancer Research</i> , 2018, 24, 4154-4161.	7.0	348
126	A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 429-440.	2.3	35



#	ARTICLE	IF	CITATIONS
127	Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience. <i>BMC Cancer</i> , 2018, 18, 693.	2.6	68
128	Pancreatic adenocarcinoma: insights into patterns of recurrence and disease behavior. <i>BMC Cancer</i> , 2018, 18, 769.	2.6	37
129	Classification of Pancreatic Cancer: Ready for Practical Application?. <i>Clinical Cancer Research</i> , 2018, 24, 4355-4356.	7.0	3
130	Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer Patients Receiving Systemic Therapy: Results of a Randomized Clinical Trial (CASSINI). <i>Blood</i> , 2018, 132, LBA-1-LBA-1.	1.4	12
131	A randomized phase 2 study of durvalumab monotherapy and in combination with tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): ALPS study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 217-217.	1.6	28
132	Pilot study of gemcitabine, nab-paclitaxel, PEGPH20, and rivaroxaban for advanced pancreatic adenocarcinoma: An interim analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, 405-405.	1.6	4
133	Synthetic Lethality: Achilles Heel in Select Patient Subpopulations. , 2018, , 257-270.		0
134	Nano-liposomal irinotecan and 5-FU/LV (N+F) for the treatment of advanced PDAC: Memorial Sloan Kettering (MSK) Single Cancer Center Evaluation.. <i>Journal of Clinical Oncology</i> , 2018, 36, 471-471.	1.6	0
135	Development of an advance care planning paradigm for advanced cancer: person-centered oncologic care and choices (P-COCC). <i>Psycho-Oncology</i> , 2017, 26, 866-869.	2.3	18
136	Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer. <i>British Journal of Cancer</i> , 2017, 116, 697-702.	6.4	70
137	Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 2392.	7.4	670
138	Pancreatic ductal adenocarcinoma: State-of-the-art 2017 and new therapeutic strategies. <i>Cancer Treatment Reviews</i> , 2017, 60, 32-43.	7.7	116
139	A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma. <i>Cancer</i> , 2017, 123, 4556-4565.	4.1	61
140	Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 825.	7.4	366
141	Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1028-1061.	4.9	762
142	Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype. <i>Clinical Cancer Research</i> , 2017, 23, 6094-6100.	7.0	161
143	The oral microbiota in patients with pancreatic cancer, patients with IPMNs, and controls: a pilot study. <i>Cancer Causes and Control</i> , 2017, 28, 959-969.	1.8	69
144	Ablative Radiotherapy Doses for Locally Advanced. <i>Cancer Journal (Sudbury, Mass )</i> , 2017, 23, 350-354.	2.0	14

#	ARTICLE	IF	CITATIONS
145	Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results. <i>Oncologist</i> , 2017, 22, 1429-e139.	3.7	31
146	Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer. <i>Acta Oncol</i> , 2017, 56, 1746-1753.	1.8	38
147	Chemotherapy and intensity-modulated radiation therapy for locally advanced pancreatic cancer achieves a high rate of R0 resection*. <i>Acta Oncol</i> , 2017, 56, 384-390.	1.8	24
148	Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2135-2145.	3.4	53
149	Preliminary study of tumor heterogeneity in imaging predicts two year survival in pancreatic cancer patients. <i>PLoS ONE</i> , 2017, 12, e0188022.	2.5	69
150	Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas. <i>BMC Cancer</i> , 2017, 17, 505.	2.6	166
151	Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients. <i>World Journal of Surgical Oncology</i> , 2017, 15, 183.	1.9	112
152	Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance). <i>Journal of Clinical Oncology</i> , 2017, 35, 3671-3677.	1.6	112
153	Case report: primary acinar cell carcinoma of the liver treated with multimodality therapy. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, E65-E72.	1.4	4
154	An elderly man with remote history of metastatic melanoma now with localized pancreas cancer and new liver masses. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 596-602.	1.4	0
155	Prospective assessment for pathogenic germline alterations (PGA) in pancreas cancer (PAC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4102-4102.	1.6	4
156	Single agent HuMab-5B1 (MVT-5873), a monoclonal antibody targeting sLe <sup>a</sup> , in patients with pancreatic cancer and other CA19-9 positive malignancies.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4110-4110.	1.6	4
157	Clinical characterization of pancreatic ductal adenocarcinomas (PDAC) with mismatch repair (MMR) gene mutations.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15791-e15791.	1.6	2
158	Acceptability and effects of values-based outpatient advance care planning (ACP) in gastrointestinal (GI) cancers.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9-9.	1.6	1
159	Results of a randomized phase II trial of an anti-notch 2/3, tarextumab (OMP-59R5, TRXT, anti-Notch2/3), in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 279-279.	1.6	16
160	Two randomized, placebo-controlled phase 3 studies of ruxolitinib (Rux) + capecitabine (C) in patients (pts) with advanced/metastatic pancreatic cancer (mPC) after failure/intolerance of first-line chemotherapy: JANUS 1 (J1) and JANUS 2 (J2).. <i>Journal of Clinical Oncology</i> , 2017, 35, 343-343.	1.6	17
161	Necuparanib combined with nab-paclitaxel + gemcitabine in patients with metastatic pancreatic cancer: Phase 2 results.. <i>Journal of Clinical Oncology</i> , 2017, 35, 370-370.	1.6	5
162	Pancreas adenocarcinoma: novel therapeutics. <i>Chinese Clinical Oncology</i> , 2017, 6, 30-30.	1.2	14

#	ARTICLE	IF	CITATIONS
163	Preface: pancreas adenocarcinoma. <i>Chinese Clinical Oncology</i> , 2017, 6, 23-23.	1.2	0
164	Preface for Special Edition Pancreas Cancer. <i>Chinese Clinical Oncology</i> , 2017, 6, 57-57.	1.2	0
165	Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer?. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 738-749.	1.4	14
166	Weight Loss, Diabetes, Fatigue, and Depression Preceding Pancreatic Cancer. <i>Pancreas</i> , 2016, 45, 986-991.	1.1	61
167	Texture analysis for survival prediction of pancreatic ductal adenocarcinoma patients with neoadjuvant chemotherapy. , 2016, , .		4
168	Pancreas Adenocarcinoma: Ascites, Clinical Manifestations, and Management Implications. <i>Clinical Colorectal Cancer</i> , 2016, 15, 360-368.	2.3	30
169	ReCAP: Hospitalizations in Older Adults With Advanced Cancer: The Role of Chemotherapy. <i>Journal of Oncology Practice</i> , 2016, 12, 151-152.	2.5	25
170	Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic Cancer. <i>Cell Reports</i> , 2016, 16, 2017-2031.	6.4	84
171	Current management and future directions in metastatic pancreatic adenocarcinoma. <i>Cancer</i> , 2016, 122, 3765-3775.	4.1	18
172	Management of Metastatic Pancreatic Adenocarcinoma. <i>Surgical Clinics of North America</i> , 2016, 96, 1391-1414.	1.5	10
173	Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2016, 34, 2784-2796.	1.6	267
174	Discussions of Life Expectancy and Changes in Illness Understanding in Patients With Advanced Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2398-2403.	1.6	179
175	Early Detection and Treatment Opportunities in Pancreatic Adenocarcinoma. <i>Journal of Oncology Practice</i> , 2016, 12, 31-32.	2.5	0
176	Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 1-13.	3.0	39
177	Intensity modulated radiation therapy reduces gastrointestinal toxicity in locally advanced pancreas cancer. <i>Practical Radiation Oncology</i> , 2016, 6, 78-85.	2.1	30
178	Gemcitabine-Related Pneumonitis in Pancreas Adenocarcinoma—An Infrequent Event: Elucidation of Risk Factors and Management Implications. <i>Clinical Colorectal Cancer</i> , 2016, 15, 24-31.	2.3	13
179	Adjuvant and Neoadjuvant Therapy for Pancreatic Cancer. <i>Surgical Oncology Clinics of North America</i> , 2016, 25, 311-326.	1.5	19
180	Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine. <i>Gastroenterology</i> , 2016, 150, 48-63.	1.3	90

#	ARTICLE	IF	CITATIONS
181	Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy. Expert Opinion on Therapeutic Targets, 2016, 20, 341-359.	3.4	34
182	A novel scoring system to predict survival in patients with advanced pancreatic adenocarcinoma: The Memorial Prognostic Score (MPS).. Journal of Clinical Oncology, 2016, 34, 36-36.	1.6	1
183	Second-line chemotherapy (CTx) outcomes in advanced biliary cancers (ABC): A retrospective multicenter analysis.. Journal of Clinical Oncology, 2016, 34, 437-437.	1.6	3
184	Identification of germline genetic mutations in patients with pancreatic cancer. Cancer, 2015, 121, 4382-4388.	4.1	167
185	Lymph Node Metastasis Predicts Disease Recurrence in a Single-Center Experience of 70 Stages 1&#x2013;3 Appendix Cancers: A Retrospective Review. Annals of Surgical Oncology, 2015, 22, 3613-3617.	1.5	22
186	Intrahepatic Cholangiocarcinoma: expert consensus statement. Hpb, 2015, 17, 669-680.	0.3	372
187	Adjuvant and Neoadjuvant Systemic Therapy for Pancreas Adenocarcinoma. Seminars in Oncology, 2015, 42, 134-143.	2.2	17
188	Pilot Trial of Combined BRAF and EGFR Inhibition in <i>BRAF</i>-Mutant Metastatic Colorectal Cancer Patients. Clinical Cancer Research, 2015, 21, 1313-1320.	7.0	240
189	Novel Therapeutics for Pancreatic Adenocarcinoma. Hematology/Oncology Clinics of North America, 2015, 29, 777-787.	2.2	15
190	FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma. Annals of Surgical Oncology, 2015, 22, 3512-3521.	1.5	135
191	Treatment, Outcomes, and Clinical Trial Participation in Elderly Patients With Metastatic Pancreas Adenocarcinoma. Clinical Colorectal Cancer, 2015, 14, 269-276.e1.	2.3	23
192	90 Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies. European Journal of Cancer, 2015, 51, 1857-1864.	2.8	26
193	Novel directions in neoadjuvant therapy for pancreas adenocarcinoma. Expert Review of Gastroenterology and Hepatology, 2015, 9, 585-601.	3.0	3
194	Abstract IA28: BRCA-mutated pancreas adenocarcinoma: Emerging therapeutic implications. , 2015, , .		1
195	Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of necuparanib combined with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer: Phase 1 results.. Journal of Clinical Oncology, 2015, 33, 4114-4114.	1.6	3
196	Final results of phase Ib of anticancer stem cell antibody tarextumab (OMP-59R5, TRXT, anti-Notch 2/3) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC).. Journal of Clinical Oncology, 2015, 33, 278-278.	1.6	8
197	Phase II trial of veliparib (V) in patients (pts) with previously treated BRCA or PALB2-mutated (mut) pancreas adenocarcinoma (PC).. Journal of Clinical Oncology, 2015, 33, 358-358.	1.6	2
198	Liver resection for metastatic colorectal leiomyosarcoma: a single center experience. Journal of Gastrointestinal Oncology, 2015, 6, E70-6.	1.4	15

#	ARTICLE	IF	CITATIONS
199	Abstract B98: Final results of a randomized phase Ib study of fractionated 90Y-clivatuzumab tetraxetan in patients with metastatic pancreatic cancer having at least two prior therapies. , 2015, , .		0
200	Liver-directed conversion therapy in metastatic colon cancer. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, 322-8.	1.4	1
201	"This is not me": patient, family, cultural and clinician considerations in cases of severe cancer-related debility. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, 589-93.	1.4	0
202	Pharmacogenomic Modeling of Circulating Tumor and Invasive Cells for Prediction of Chemotherapy Response and Resistance in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 5281-5289.	7.0	49
203	A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2014, 60, 319-324.	3.7	83
204	FOLFIRINOX induction therapy for stage III pancreatic adenocarcinoma. <i>Journal of the American College of Surgeons</i> , 2014, 219, e176.	0.5	0
205	25-Hydroxyvitamin D Levels and Survival in Advanced Pancreatic Cancer: Findings From CALGB 80303 (Alliance). <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	28
206	A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression. <i>Pancreatology</i> , 2014, 14, 398-402.	1.1	18
207	A Single-Arm, Nonrandomized Phase II Trial of Neoadjuvant Gemcitabine and Oxaliplatin in Patients With Resectable Pancreas Adenocarcinoma. <i>Annals of Surgery</i> , 2014, 260, 142-148.	4.2	121
208	DNA Mismatch Repair Abnormalities in Acinar Cell Carcinoma of the Pancreas. <i>Pancreas</i> , 2014, 43, 1264-1270.	1.1	34
209	Phase IB trial of cisplatin (C), gemcitabine (G), and veliparib (V) in patients with known or potential BRCA or PALB2-mutated pancreas adenocarcinoma (PC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 4023-4023.	1.6	17
210	Phase Ib of anticancer stem cell antibody OMP-59R5 (anti-Notch2/3) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 220-220.	1.6	5
211	Liver and Bile Duct Cancer. , 2014, , 1373-1396.e8.		5
212	A woman with metastatic pancreatic neuroendocrine tumor. <i>Gastrointestinal Cancer Research: GCR</i> , 2014, 7, 27-32.	0.7	2
213	Postoperative outcomes following pancreaticoduodenectomy: how should age affect clinical practice?. <i>World Journal of Surgical Oncology</i> , 2013, 11, 131.	1.9	16
214	Sunitinib malate for the treatment of pancreas malignancies – where does it fit?. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 783-792.	1.8	10
215	Adjuvant therapy for pancreas adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2013, 107, 78-85.	1.7	13
216	Evolving Panorama of Treatment for Metastatic Pancreas Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 1621-1623.	1.6	4

#	ARTICLE	IF	CITATIONS
217	A Randomized Controlled Trial of a Cardiopulmonary Resuscitation Video in Advance Care Planning for Progressive Pancreas and Hepatobiliary Cancer Patients. <i>Journal of Palliative Medicine</i> , 2013, 16, 623-631.	1.1	75
218	Failure Patterns in Resected Pancreas Adenocarcinoma. <i>Annals of Surgery</i> , 2013, 258, 331-335.	4.2	68
219	Prognosis of Minimally Invasive Carcinoma Arising in Mucinous Cystic Neoplasms of the Pancreas. <i>American Journal of Surgical Pathology</i> , 2013, 37, 601-605.	3.7	50
220	Targeted Agents and Systemic Therapy in Hepatocellular Carcinoma. <i>Recent Results in Cancer Research</i> , 2013, 190, 225-246.	1.8	21
221	Identification of germline genetic mutations in patients with pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 159-159.	1.6	0
222	Use of pharmacogenomic modeling in pancreatic cancer for prediction of chemotherapy response and resistance.. <i>Journal of Clinical Oncology</i> , 2013, 31, 142-142.	1.6	0
223	Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium. <i>Gastrointestinal Cancer Research: GCR</i> , 2013, 6, 3-9.	0.7	50
224	Modified GTX as Second-Line Chemotherapy in Advanced Pancreatic Cancer. <i>Gastrointestinal Cancer Research: GCR</i> , 2013, 6, 115-7.	0.7	0
225	Emerging therapies for pancreas neuroendocrine cancers. <i>Chinese Clinical Oncology</i> , 2013, 2, 23.	1.2	8
226	Postresection Surveillance for Pancreatic Cancer Performance Status, Imaging, and Serum Markers. <i>Cancer Journal (Sudbury, Mass )</i> , 2012, 18, 609-613.	2.0	13
227	Early Postoperative Intraperitoneal Chemotherapy Following Cytoreductive Surgery for Appendiceal Mucinous Neoplasms With Isolated Peritoneal Metastasis. <i>Diseases of the Colon and Rectum</i> , 2012, 55, 407-415.	1.3	16
228	Exocrine Pancreas Cancer and Thromboembolic Events: A Systematic Literature Review. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 835-846.	4.9	19
229	Unusual DNA mismatch repair-deficient tumors in Lynch syndrome: a report of new cases and review of the literature. <i>Human Pathology</i> , 2012, 43, 1677-1687.	2.0	93
230	A Novel Survival-Based Tissue Microarray of Pancreatic Cancer Validates MUC1 and Mesothelin as Biomarkers. <i>PLoS ONE</i> , 2012, 7, e40157.	2.5	99
231	Analysis of incidence and clinical outcomes in patients with thromboembolic events and invasive exocrine pancreatic cancer. <i>Cancer</i> , 2012, 118, 3053-3061.	4.1	85
232	Augmenting advance care planning in poor prognosis cancer with a video decision aid. <i>Cancer</i> , 2012, 118, 4331-4338.	4.1	66
233	Costs and trends in pancreatic cancer treatment. <i>Cancer</i> , 2012, 118, 5132-5139.	4.1	78
234	Gastrointestinal Cancer Educatinal Case Series: A 65 year-old Female with Locally Advanced Gastric Cancer and a Supraclavicular Lymph Node. <i>Journal of Gastrointestinal Cancer</i> , 2012, 43, 93-96.	1.3	1



#	ARTICLE	IF	CITATIONS
235	A Man with Klinefelter's Syndrome and New Abdominal Distension: A Discussion of Evaluation and Management. <i>Journal of Gastrointestinal Cancer</i> , 2012, 43, 314-318.	1.3	2
236	Downstaging in Pancreatic Cancer: A Matched Analysis of Patients Resected Following Systemic Treatment of Initially Locally Unresectable Disease. <i>Annals of Surgical Oncology</i> , 2012, 19, 1663-1669.	1.5	52
237	Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase 3 trial (Cancer and Leukemia Group B 80303). <i>Cancer</i> , 2012, 118, 571-578.	4.1	18
238	Gemcitabine induced myositis in patients with pancreatic cancer: case reports and topic review. <i>Journal of Neuro-Oncology</i> , 2012, 106, 15-21.	2.9	23
239	Retrospective review of doxorubicin plus sorafenib as second-line therapy in hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 298-298.	1.6	4
240	Communication and palliative care in a 64-year-old man with pancreatic adenocarcinoma. <i>Gastrointestinal Cancer Research: GCR</i> , 2012, 5, 130-4.	0.7	2
241	A Nonrandomized, Phase II Study of Sequential Irinotecan and Flavopiridol in Patients With Advanced Hepatocellular Carcinoma. <i>Gastrointestinal Cancer Research: GCR</i> , 2012, 5, 185-9.	0.7	7
242	New Approaches to the Treatment of Pancreatic Cancer. <i>BioDrugs</i> , 2011, 25, 207-216.	4.6	10
243	Synchronous Epithelial and Neuroendocrine Cancers of the Pancreas: Case Series of a Rare Occurrence. <i>Clinical Colorectal Cancer</i> , 2011, 10, 146-150.	2.3	3
244	Targeting Mutated K-ras in Pancreatic Adenocarcinoma Using an Adjuvant Vaccine. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 321-325.	1.3	97
245	MicroRNA, hypoxic stress and hepatocellular carcinoma: Future directions. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 1586-1588.	2.8	3
246	A 67-Year-Old Woman with BRCA 1 Mutation Associated with Pancreatic Adenocarcinoma. <i>Journal of Gastrointestinal Cancer</i> , 2011, 42, 160-164.	1.3	12
247	Gastrointestinal Cancer Educational Case Series: Management of Metastatic Adenocarcinoma of Unknown Primary Origin in a Ph+ ALL Survivor. <i>Journal of Gastrointestinal Cancer</i> , 2011, 42, 165-170.	1.3	2
248	A Woman with Remotely Treated Pancreas Cancer and New Abdominal Pain: A Discussion of Evaluation and Management. <i>Journal of Gastrointestinal Cancer</i> , 2011, 42, 236-240.	1.3	1
249	An Emerging Entity: Pancreatic Adenocarcinoma Associated with a Known BRCA Mutation: Clinical Descriptors, Treatment Implications, and Future Directions. <i>Oncologist</i> , 2011, 16, 1397-1402.	3.7	227
250	Building on Individual, State, and Federal Initiatives for Advance Care Planning, an Integral Component of Palliative and End-of-Life Cancer Care. <i>Journal of Oncology Practice</i> , 2011, 7, 355-359.	2.5	13
251	Electronic Chemotherapy Order Entry: A Major Cancer Center's Implementation. <i>Journal of Oncology Practice</i> , 2011, 7, 213-218.	2.5	12
252	Adjuvant therapy for pancreas adenocarcinoma: where are we going?. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 173-177.	2.4	7



#	ARTICLE	IF	CITATIONS
253	Targeting thrombosis in exocrine pancreas cancer: a continued need for improved therapies. Expert Review of Anticancer Therapy, 2011, 11, 1783-1785.	2.4	0
254	Acinar Cell Carcinoma of the Pancreas: New Genetic and Treatment Insights into a Rare Malignancy. Oncologist, 2011, 16, 1714-1720.	3.7	121
255	Targeted Therapies for Hepatocellular Carcinoma. , 2011, , 355-368.		0
256	Pancreatic islet cell carcinoma presenting with concurrent Cushing's and Zollingerâ€“Ellison syndromes: case series and literature review. European Journal of Gastroenterology and Hepatology, 2010, 22, 246-252.	1.6	6
257	Hepatocellular carcinoma in two patients with cardiac cirrhosis. European Journal of Gastroenterology and Hepatology, 2010, 22, 889-891.	1.6	84
258	Capsule-Induced Small-Bowel Obstruction During Video Capsule Endoscopy in a Patient with Carcinomatosis. Digestive Diseases and Sciences, 2010, 55, 1778-1780.	2.3	1
259	Pain and Emotional Well-Being Outcomes in Southwest Oncology Groupâ€“Directed Intergroup Trial S0205: A Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine As First-Line Therapy in Patients With Advanced Pancreas Cancer. Journal of Clinical Oncology, 2010, 28, 3611-3616.	1.6	21
260	Advanced Hepatocellular Carcinoma: Which Staging Systems Best Predict Prognosis?. Journal of Clinical Oncology, 2010, 28, 2889-2895.	1.6	286
261	A Cancer and Leukemia Group B Phase II Study of Sunitinib Malate in Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma (CALGB 80603). Oncologist, 2010, 15, 1310-1319.	3.7	58
262	Refinement of Adjuvant Therapy for Pancreatic Cancer. JAMA - Journal of the American Medical Association, 2010, 304, 1124.	7.4	26
263	Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Groupâ€“Directed Intergroup Trial S0205. Journal of Clinical Oncology, 2010, 28, 3605-3610.	1.6	570
264	Pancreatic adenocarcinoma in a young patient populationâ€“12â€“year experience at Memorial Sloan Kettering Cancer Center. Journal of Surgical Oncology, 2009, 100, 8-12.	1.7	31
265	Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer. Investigational New Drugs, 2009, 27, 366-373.	2.6	4
266	Combined Modality Treatment of Resectable and Borderline Resectable Pancreas Cancer: Expert Consensus Statement. Annals of Surgical Oncology, 2009, 16, 1751-1756.	1.5	267
267	Phase I Study of Weekly Cisplatin, Bolus Fluorouracil and Escalating Doses of Irinotecan in Advanced Solid Tumors. Cancer Investigation, 2009, 27, 402-406.	1.3	1
268	A Phase II Study of Flavopiridol (Alvocidib) in Combination with Docetaxel in Refractory, Metastatic Pancreatic Cancer. Pancreatology, 2009, 9, 404-409.	1.1	37
269	Indications for Neoadjuvant, Adjuvant, and Palliative Chemotherapy in the Treatment of Biliary Tract Cancers. Surgical Oncology Clinics of North America, 2009, 18, 361-379.	1.5	5
270	Lack of Splenic Uptake of In-111 Pentetreotide Due to Splenic Embolization. Clinical Nuclear Medicine, 2009, 34, 960-961.	1.3	0

#	ARTICLE	IF	CITATIONS
271	Accomplishments in 2008 in the management of localized pancreatic cancer. <i>Gastrointestinal Cancer Research: GCR</i> , 2009, 3, S37-42.	0.7	2
272	Phase II trial of sequential paclitaxel and 1Âh infusion of bryostatin-1 in patients with advanced esophageal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 875-880.	2.3	50
273	Gallbladder cancer (GBC): 10Âyear experience at Memorial SloanâKettering Cancer Centre (MSKCC). <i>Journal of Surgical Oncology</i> , 2008, 98, 485-489.	1.7	375
274	Pathologic Complete Response to Neoadjuvant FOLFOX in Combination with Bevacizumab in Unresectable Metastatic Colorectal Carcinoma. <i>Clinical Colorectal Cancer</i> , 2008, 7, 140-143.	2.3	3
275	Collision Tumor of the Large Bowel in the Context of Advanced Pregnancy and Ulcerative Colitis. <i>Clinical Colorectal Cancer</i> , 2008, 7, 402-405.	2.3	10
276	Comparison of gemcitabine plus platinum analog with gemcitabine alone in advanced pancreatic cancer. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 312-313.	4.3	3
277	Liver and Bile Duct Cancer. , 2008, , 1569-1594.		1
278	Cytotoxic Therapy for Advanced Pancreatic Adenocarcinoma. <i>Seminars in Oncology</i> , 2007, 34, 347-353.	2.2	63
279	Randomized Phase III Study of Exatecan and Gemcitabine Compared With Gemcitabine Alone in Untreated Advanced Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 4441-4447.	1.6	254
280	A Phase II Study of Intravenous Exatecan Administered Daily for 5 Days, Every 3 Weeks to Patients With Biliary Tract Cancers. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2005, 28, 334-339.	1.3	10
281	Biliary tract cancers: current concepts and controversies. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 211-223.	1.8	27
282	Phase II Trial of 96-Hour Paclitaxel in Previously Treated Patients with Advanced Esophageal Cancer. <i>Cancer Investigation</i> , 2003, 21, 512-516.	1.3	22
283	Phase I Trial of Escalating-Dose Irinotecan Given Weekly With Cisplatin and Concurrent Radiotherapy in Locally Advanced Esophageal Cancer. <i>Journal of Clinical Oncology</i> , 2003, 21, 2926-2932.	1.6	96
284	Phase I Study of the Cyclin-Dependent Kinase Inhibitor Flavopiridol in Combination With Paclitaxel in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2002, 20, 2157-2170.	1.6	157
285	Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV disease. <i>Annals of Surgical Oncology</i> , 2002, 9, 954-960.	1.5	65
286	Radical Resection of Rectal Cancer Primary Tumor Provides Effective Local Therapy in Patients With Stage IV Disease. <i>Annals of Surgical Oncology</i> , 2002, 9, 954-960.	1.5	3
287	Phase II Study of the Cyclin-Dependent Kinase Inhibitor Flavopiridol Administered to Patients With Advanced Gastric Carcinoma. <i>Journal of Clinical Oncology</i> , 2001, 19, 1985-1992.	1.6	198
288	Surgical Debulking and Intraperitoneal Chemotherapy for Established Peritoneal Metastases From Colon and Appendix Cancer. <i>Annals of Surgical Oncology</i> , 2001, 8, 787-795.	1.5	124

#	ARTICLE	IF	CITATIONS
289	A Phase II study of irinotecan in patients with advanced hepatocellular carcinoma. <i>Cancer</i> , 2001, 91, 101-105.	4.1	80
290	Surgical Debulking and Intraperitoneal Chemotherapy for Established Peritoneal Metastases From Colon and Appendix Cancer. <i>Annals of Surgical Oncology</i> , 2001, 8, 787-795.	1.5	6
291	A Phase II Trial of Interferon Alpha-2a and Carboplatin in Patients with Advanced Malignant Mesothelioma. <i>Cancer Investigation</i> , 1999, 17, 195-200.	1.3	29
292	Non-Hodgkin Lymphoma as a Cause of Intrahepatic Periportal Low Attenuation on CT. <i>Journal of Computer Assisted Tomography</i> , 1997, 21, 726-728.	0.9	19
293	Precision Approaches to Pancreatic Cancer Therapy: What Now and What Next?. <i>Current Treatment Options in Gastroenterology</i> , 0, , .	0.8	0